Jane Armitage

发表

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals

Andrew Briggs, Sarah Parish, Alastair Gray, 2005, The Lancet.

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people

Andrew Briggs, Sarah Parish, Alastair Gray, 2006, BMJ : British Medical Journal.

Interpretation of the evidence for the efficacy and safety of statin therapy

Peter Sandercock, Bruce Neal, Liam Smeeth, 2016, The Lancet.

The impact of privacy and confidentiality laws on the conduct of clinical trials

Lawrence H. Muhlbaier, L. Muhlbaier, J. Armitage, 2008, Clinical trials.

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

Sarah Parish, R. Collins, R. Peto, 2003, The Lancet.

Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals

J Michael Gaziano, Stein Emil Vollset, JoAnn E Manson, 2013, The Lancet.

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

John Fuller, Luigi Tavazzi, John Wikstrand, 2019, The Lancet.

Effects of extended-release niacin with laropiprant in high-risk patients.

Sarah Parish, Lixin Jiang, Jemma C Hopewell, 2014, The New England journal of medicine.

The safety of statins in clinical practice

J. Armitage, Jane Armitage, 2007, The Lancet.

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

Jemma C. Hopewell, Sarah Parish, Robert Clarke, 2012, European heart journal.